Contract

Laboratory Technician Immunoassay

Laboratory Technician, Clinical Biomarker Laboratory

Updated on 7/21/2026

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Oxford, UK

In Person

Site-based role; not eligible for remote work. Occasional overtime/weekend shifts may be required.

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Moderna

Find people who can refer or advise you

Requirements
  • BSC/MSc Degree in Biology, Biotechnology or Life sciences with experience in a lab environment
  • Demonstrated level of independence and work ethics
  • Good written, presentation and interpersonal communication skills
  • Good computational skills, preferably experienced with Word, Excel, Power Point, GraphPad Prism
  • Preferable knowledge of working in a regulated environment (GCP, ISO standards)
  • Preferable experience with LIMS systems
  • This position is site-based, requiring you to be at Moderna’s site full-time. This position is not eligible for remote work
  • As part of Moderna’s commitment to workplace safety, this role may require an enhanced pre-employment check
Responsibilities
  • Under the guidance of the study lead, take responsibility for the quality and integrity of assigned immunoassay projects supporting clinical trials at Moderna
  • Execute experimental work for assay development, qualification, and validation, as well as testing clinical samples
  • Conduct assay sample analysis and deliver high-quality data within defined timelines
  • Prepare laboratory experiments, including media, chemicals, and reagents, ensuring accurate batch record maintenance
  • Maintain laboratory space and support equipment maintenance to ensure operational excellence
  • Be trained in and adhere to Moderna-specific procedures and standards
  • Collaborate effectively across multiple projects, acting as a strong communicator to coordinate competing priorities
  • Identify, troubleshoot, and resolve quality issues, escalating to study or scientific leads as needed
  • May author bioanalytical plans and reports, and draft or review standard operating procedures (SOPs)
  • Ensure strict compliance with safety and regulatory guidelines at all times
  • Maintain up-to-date training records and demonstrate continuous learning
  • Assume general laboratory responsibilities as assigned to support team objectives
  • Operate primarily within a laboratory environment (≥85% of time), with flexibility for occasional overtime or weekend shifts as required

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • mRESVIA provides near-term RSV revenue and public-sector procurement upside.
  • mRNA flu and combination vaccines could extend recurring seasonal vaccine sales.
  • Cancer vaccine trials and autoimmune programs broaden the platform beyond respiratory vaccines.

What critics are saying

  • COVID-19 sales remain the core commercial base and continue shrinking.
  • RSV and flu programs face entrenched competitors and uncertain payer adoption.
  • Cancer and autoimmune pipelines remain unproven, so setbacks can reset valuation.

What makes Moderna unique

  • mRNA platform programs drugs by instructing cells to make proteins.
  • Moderna focuses on infectious disease, oncology, rare disease, and autoimmunity.
  • Headquartered in Cambridge, Massachusetts, with approved RSV and COVID-19 vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

1%
Natural News
Jul 21st, 2026
Moderna Launches mRNA Cancer Vaccine Trial; Experts Cite Safety Concerns

Moderna launches mRNA cancer Vaccine Trial; experts cite safety concerns. Moderna has initiated a clinical trial for an mRNA-based cancer vaccine, the company announced. According to a report by Children's Health Defense, Moderna is developing mRNA vaccines targeting cancer, shingles and herpes, expanding its pipeline beyond COVID-19 [1]. NaturalNews.com reported that the company plans to dominate the global market for mRNA-based products including vaccines [2]. The product is designed to stimulate the immune system to attack tumor cells, according to the company. The trial is expected to enroll patients with certain types of cancer, though specific enrollment numbers and trial phases were not disclosed in the announcements. Moderna has previously received regulatory designations for some of its mRNA products, including Breakthrough Therapy Designation for an RSV shot [3]. Trial design and regulatory oversight. The new trial is being conducted under the oversight of the U.S. Food and Drug Administration. However, critics have raised concerns about the regulatory process for mRNA technology. A report on Mercola.com stated that the FDA and the Centers for Disease Control and Prevention have been "derelict in their duties" regarding the Vaccine Adverse Events Reporting System, noting that safety signals have been evident since early 2021 [3]. Another Mercola.com report said that Pfizer classified almost all severe adverse events that occurred during its Phase 3 COVID-19 vaccine trials as unrelated to the injection [4]. Scientists and legal experts have petitioned the FDA to suspend or withdraw the Pfizer and Moderna mRNA COVID-19 vaccines, arguing they are unapproved gene therapies and are contaminated with DNA plasmids, according to a report by Children's Health Defense [6]. Experts warn of unanswered safety questions. Several independent researchers have expressed concerns about the long-term safety of mRNA-based cancer therapies. According to a report by Children's Health Defense, scientists warn that Moderna's COVID-19 shots may be suppressing immune function, reactivating latent viruses and potentially causing the very conditions the new products aim to prevent [7]. A South Korean study of over 8 million people reported an increased overall cancer risk of 27% linked to mRNA and non-mRNA COVID-19 vaccines, according to Children's Health Defense [8]. A preprint study presented the first direct evidence that genetic material from mRNA COVID-19 vaccines can integrate into the human genome, potentially triggering aggressive cancers, contradicting assurances that the shots cannot alter DNA [9]. The spike protein produced by mRNA vaccines has been linked to various adverse effects. In the book "Geoengineered Transhumanism," Elana Freeland discusses how the spike protein binds angiotensin converting enzyme 2 and may contribute to neurological degenerative diseases [10]. The book "The Contagion Myth" by Sally Fallon Morell and Thomas S. Cowan questions the safety of adjuvants and preservatives added to vaccines [11]. Previous mRNA Vaccine risks and debate. Previous mRNA vaccine trials have been halted due to safety issues. Moderna paused its Phase 1 trial of an mRNA vaccine for the Epstein-Barr virus after a single suspected case of myocarditis in an adolescent, raising questions about the heart-damaging technology used in all mRNA vaccines, according to a report by Children's Health Defense [12]. Critics have also pointed to contaminants found in mRNA vaccines. Microbiologist Kevin McKernan, a former researcher for the Massachusetts Institute of Technology Human Genome Project, said he discovered simian virus 40 (SV40) in mRNA COVID-19 vaccines, a virus linked to mesotheliomas, lymphomas and cancers of the brain and bone, according to a report by Children's Health Defense [13]. Health Canada confirmed the presence of DNA plasmid contamination in Pfizer COVID-19 vaccines and confirmed that Pfizer did not disclose the contamination to the health authority [14]. Furthermore, the same companies developing mRNA cancer therapies are those that produced the COVID-19 shots. A Brighteon Broadcast News episode noted that Moderna and Pfizer sought a court order to conceal clinical data for 75 years, which would have effectively erased the ability to trace adverse effects back to the original vaccine administration [15]. Conclusion: balancing hope and caution. Moderna's expansion into cancer treatment represents a significant step for the company, according to its executives. However, the safety record of mRNA technology remains under scrutiny following widespread administration of the COVID-19 vaccines. The outcome of the new trial will provide data on both efficacy and long-term safety, researchers said. Some experts recommend rigorous independent monitoring and extended follow-up for trial participants. Until more comprehensive safety data are available, caution is warranted. The trial's results will be closely watched by the medical community and the public alike. References. * Children's Health Defense. "Moderna Developing mRNA Vaccines for Cancer, Shingles and Herpes". ChildrensHealthDefense.org. * NaturalNews.com. "Moderna plans to release mRNA vaccines for other diseases including cancer". NaturalNews.com. January 30, 2023. * Mercola.com. "Coming Soon The Worlds Stupidest Vaccine". Mercola.com. February 09, 2023. * Mercola.com. "Why Doctors Dont Care About COVID Jab Side E". November 11, 2022. * Mercola.com. "Is This Why Pfizer Wanted Trial Data Buried f". July 05, 2022. * Children's Health Defense. "Scientists Petition FDA to Suspend or Withdraw mRNA COVID Vaccines". * Children's Health Defense. "Moderna Developing mRNA Vaccines for Diseases Linked to COVID Shots". * Children's Health Defense. "All COVID Vaccines Increase Cancer Risk, New Study Concludes". * Children's Health Defense. "'Alarm Bells': Genetic 'Fingerprint' of COVID Vaccine Found in 31-Year-Old Cancer Patient's DNA". * Elana Freeland. "Geoengineered Transhumanism". * Sally Fallon Morell and Thomas S. Cowan. "The Contagion Myth Why Viruses Are Not the Cause of Disease". * Children's Health Defense. "Moderna Halts Epstein-Barr mRNA Vaccine Trial After Myocarditis Case". * Children's Health Defense. "SV40 Virus Linked to Multiple Cancers Found in mRNA Vaccines, Microbiologist Says". * Children's Health Defense. "'An Admission of Epic Proportions': Health Canada Confirms DNA Plasmid Contamination of COVID Vaccines". * Mike Adams. "Brighteon Broadcast News". Ask BrightAnswers.ai Related Topics

Society of Chemical Industry
Jul 9th, 2026
UK life sciences attracts £3bn investment in 12 months.

UK life sciences attracts £3bn investment in 12 months. 9 July 2026 | Muriel Cozier The UK's Life Sciences Sector Plan, published 12 months ago, has helped to attract more than £3 billion in public and private investment to the country, reflecting international confidence in the UK's world-class science, innovation and health ecosystem, the government has said. Major private investments, which the government describes as "creating hotbeds of innovation and revitalising regional economies up and down the country" include: £300 million backing from AstraZeneca to support its operations in its Cambridge headquarters and a facility in Macclesfield using AI to discover new drugs; Moderna opening its new innovation centre in Harwell with a £1 billion UK R&D investment commitment over the next 10 years; and UCB's £500 million investment in a new world-class R&D hub in Windlesham, Surrey, developing a range of transformative medicines for immunological diseases. The Life Sciences Sector Plan, which is part of the UK government's wider Modern Industrial Strategy, published in July 2025, outlines targeted actions to support world-class research and development, attract investment, grow advanced manufacturing and accelerate health innovation. The plan aims to position the UK as the leading life science economy in Europe by 2035, behind only the US and China. "In its first year, our Life Sciences Sector Plan is delivering cutting-edge treatments to tackle cancer, new opportunities for British businesses to start up and grow, and well-paid jobs that improve lives for families. A thriving life sciences sector is good for NHS patients and good for economic growth across the UK," said Liz Kendell, Science Innovation and Technology Secretary. Pascal Soriot, CEO AstraZeneca said: "2026 has been an important year of tangible action advancing UK life sciences. The first ever increase of the NICE threshold since 1999, the establishment of the Health Data Research Service, and measures to speed up clinical trial delivery. We look forward to working with the government to further strengthen its global competitiveness and build on this momentum." Setting out the achievements in a report: Life Sciences Sector Plan Year One Update, the government said that progress has been made in four specific areas: investment in commercial research and development; access to scale-up capital; patient access; and foreign direct investment. The report notes: "We are also deepening our partnerships with industry to accelerate and deliver tangible benefits for patients. This includes our collaboration with Lilly on the £85 million Obesity Pathway Innovation Programme, and the Respiratory Transformation Partnership with AstraZeneca, Chiesi, GSK and Sanofi, demonstrating how coordinated action across industry and the NHS can test new models of care, improve access to treatment and support better health outcomes." Considering the developments in the global context the report says: "We have done this in a challenging global environment. Competition for investment has intensified, and pressures across supply chains and trade continue to shape the operating environment for businesses. In this context, we have worked closely with industry to provide stability, back innovation and support growth, strengthening our international partnerships and supporting improved market access for UK life sciences exports." The government also highlighted the UK's relationship with the US, saying that the UK-US Pharmaceuticals Arrangement, published in April 2026, secured a commitment to no additional tariffs on pharmaceuticals or medtech exports under US Section 232 or Section 301 investigations for at least three years. "The UK is the first and only country to secure these commitments which provide certainty for UK exporters, reduce supply chain risk and strengthen the UK's position as a globally competitive location for life sciences manufacturing and innovation," the government said. Professor Chris Molloy, CEO of the UK BioIndustry Association (BIA) said: "The US-UK pharmaceutical deal provides a framework for purposeful, evidence-based collaboration between industry and government to improve patient access to the latest innovative medicines. But in an increasingly competitive world, simply going faster than before is not enough. Pace is paramount and we need a fundamental change of gear to accelerate to the front of the pack - particularly in unlocking high-volume domestic finance, from company proof of concept through to scale-up, speeding up clinical trials and patients' access to the latest medicines." Further reading:

NPR
Jun 19th, 2026
FDA committee unanimously backs first vaccine since 2023, Moderna's mRNA flu shot

The FDA's vaccine advisory committee unanimously recommended Moderna's mRNA influenza vaccine, mFlusiva, for adults aged 50 and over on Thursday. This marks the committee's first review of a new vaccine application since 2023. All nine members of the Vaccines and Related Biological Products Advisory Committee voted in favour despite sustained vaccine criticism from President Trump and HHS Secretary Robert F Kennedy Jr, who previously cancelled nearly $500 million in mRNA vaccine development contracts. The mRNA flu vaccine uses the same technology as COVID-19 vaccines and can be produced faster than traditional flu vaccines. Moderna's phase 3 trial showed the vaccine produced longer-lasting responses and antibodies recognising more flu strains. Over 6 billion mRNA vaccine doses have been administered globally since 2020. If approved, the vaccine could be available next flu season.

Midwest Communications, Inc.
Jun 15th, 2026
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study.

Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study. By Thomson Reuters Jun 15, 2026 | 9:58 AM By Sahil Pandey and Mariam Sunny June 15 (Reuters) - Elicio Therapeutics shares fell about 72% on Monday after the biotech firm's experimental pancreatic cancer vaccine failed to significantly extend the time patients lived without their disease returning, missing the main goal of a mid-stage study. The therapy, ELI-002 7P, is designed to deliver the treatment directly to the lymph nodes to boost immune responses against the cancer. The study enrolled 144 patients with pancreatic cancer linked to mutations in the KRAS gene, who had undergone surgery and standard treatment and were radiographically free of disease at enrolment, the company said. Elicio said about 19% of patients who received the treatment had higher levels of residual disease, increasing the risk of relapse, compared with about 10% in the control group, an imbalance the company said weighed on results. The trial carried the burden of generating the first randomized efficacy data for a KRAS-targeted cancer vaccine and its broad enrolment, regardless of residual disease, "may have blunted the detectable treatment effect," B. Riley analyst Mayank Mamtani said. He added that the "go-forward case" now rests on the late-stage study, which focuses on the patients with lower residual disease and evaluating additional dosing. Moderna is developing a personalized cancer vaccine, intismeran autogene, in combination with Merck's blockbuster drug Keytruda in patients with skin cancer. Unlike personalized treatments that must be custom-made for each patient, ELI-002 7P is ready to use, which simplifies manufacturing and reduces cost, Mamtani said. In patients with complete surgical clearance of cancer, representing about 84% of the study population, the therapy achieved an average disease-free survival of 23.8 months versus 12.8 months for control arm, which received only the standard-of-care, Elicio said. The therapy also showed a favorable safety profile, with no treatment-related discontinuations and fewer adverse events than the control arm, supporting potential long-term use and combination approaches, Elicio said. Elicio said it is currently evaluating multiple strategic financing and partnership opportunities. (Reporting by Sahil Pandey and Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)

BOL News
Jun 11th, 2026
New AI tool detects brain tumors in minutes instead of days.

New AI tool detects brain tumors in minutes instead of days. Heteros demonstrates how AI-enabled digital pathology can revolutionize medical diagnostics. * Web Desk * June 11, 2026 HEIDELBERG, Germany: Scientists have developed an advanced artificial intelligence (AI) system capable of diagnosing brain tumors in just 12 minutes, a dramatic improvement over the current average diagnostic time of about 12 days. Researchers in Heidelberg, Germany, created the AI platform, known as Heteros, which can identify and classify brain tumors with remarkable speed and accuracy. Experts say the technology has the potential to transform the diagnosis of brain cancer worldwide. In recent years, researchers have found that many brain tumors can only be accurately diagnosed through detailed analysis of both their molecular characteristics and microscopic structure. However, such testing is often complex, requires specialized equipment, and can take up to two weeks to produce results. To address these challenges, German scientists developed the AI-powered system to make brain cancer diagnosis faster, simpler, and more accessible. Moritz Gerstung, a researcher at the German Cancer Research Center and one of the leaders of the project, said Heteros demonstrates how AI-enabled digital pathology can revolutionize medical diagnostics. He said the technology allows for rapid and widely accessible diagnostic methods that previously required highly sophisticated technical resources, potentially improving patient care and speeding up treatment decisions for those with brain cancer. Earlier, Researchers at the University of Oxford and pharmaceutical company Moderna have developed an experimental mRNA vaccine aimed at preventing cancer in people at high risk of developing bowel and ovarian cancers. The vaccine, however, has yet to undergo clinical testing and remains in the trial phase. Scientists say the vaccine is based on mRNA technology, which could eventually be used to prevent a wider range of cancers in the future. The research focuses on people with Lynch syndrome, an inherited condition that significantly increases the risk of several cancers, including those affecting the bowel, uterus, ovaries, stomach, pancreas, kidneys and skin.